Kinetics of regulatory dendritic cells in inflammatory responses during Trypanosoma evansi infection

Parasite Immunology

Volumn 34, Issue 6, 2012, Pages 318-329

  Mekata, H ^a   Konnai, S ^a   Mingala, C N ^b   Abes, N S ^b   Gutierrez, C A ^b   Dargantes, A P ^c   Witola, W H ^d   Inoue, N ^e   Onuma, M ^a   Murata, S ^a   Ohashi, K ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Philippine Carabao Center National Headquarters and Genepool   (Philippines)

^c CENTRAL MINDANAO UNIVERSITY   (Philippines)

^d TUSKEGEE UNIVERSITY   (United States)

^e OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE   (Japan)

Author keywords

CCL8; Cytokine storm; IL 10; Regulatory dendritic cell; T. evansi

Indexed keywords

INTERLEUKIN 10; MONOCYTE CHEMOTACTIC PROTEIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; INFLAMMATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENICITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPLEEN CELL; SURRA; SURVIVAL; TRYPANOSOMA EVANSI;

ANIMALS; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MICE, INBRED BALB C; MICROARRAY ANALYSIS; TRYPANOSOMA; TRYPANOSOMIASIS;

MAMMALIA; MUS; TRYPANOSOMA EVANSI;

EID: 84860910128     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2012.01362.x     Document Type: Article

References (61)

1. Lun ZR & Desser SS. Is the broad range of hosts and geographical distribution of Trypanosoma evansi attributable to the loss of maxicircle kinetoplast DNA? Parasitol Today 1995; 11: 131-133.
2. Reid S. Trypanosoma evansi control and containment in Australasia. Trends Parasitol 2002; 18: 219-224.
3. Sumba AL, Mihok S & Oyieke FA. Mechanical transmission of Trypanosoma evansi and T. congolense by Stomoxys niger and S. taeniatus in a laboratory mouse model. Med Vet Entomol 1998; 12: 417-422.
4. Otte MJ & Abuabara JY. Transmission of South American Trypanosoma vivax by the neotropical horsefly Tabanus nebulosus. Acta Trop 1991; 49: 73-76.
5. Boid R, Jones TW & Payne RC. Malic enzyme type VII isoenzyme as an indicator of suramin resistance in Trypanosoma evansi. Exp Parasitol 1989; 69: 317-323.
6. El Rayah IE, Kaminsky R, Schmid C & El Malik KH. Drug resistance in Sudanese Trypanosoma evansi. Vet Parasitol 1999; 80: 281-287.
7. Hertz C, Filutowicz H & Mansfield J. Resistance to the African trypanosomes is IFN-γ dependent. J Immunol 1998; 161: 6775-6783.
8. Magez S, Radwanska M, Drennan M, et al. Interferon-γ and nitric oxide in combination with antibodies are key protective host immune factors during Trypanosoma congolense Tc13 infections. J Infect Dis 2006; 193: 1575-1583.
9. Naessens J, Kitani H, Momotani E, Sekikawa K, Nthale JM & Iraqi F. Susceptibility of TNF-α-deficient mice to Trypanosoma congolense is not due to a defective antibody response. Acta Trop 2004; 92: 193-203.
10. Magez S, Geuskens M, Beschin A, et al. Specific uptake of tumor necrosis factor-α is involved in growth control of Trypanosoma brucei. J Cell Biol 1997; 137: 715-727.
11. Masocha W, Robertson B, Rottenberg ME, Mhlanga J, Sorokin L & Kristensson K. Cerebral vessel laminins and IFN-γ define Trypanosoma brucei brucei penetration of the blood-brain barrier. J Clin Invest 2004; 114: 689-694.
12. Magez S, Radwanska M, Beschin A, Sekikawa K & De Baetselier P. Tumor necrosis factor-α is a key mediator in the regulation of experimental Trypanosoma brucei infections. Infect Immun 1999; 67: 3128-3132.
13. Magez S, Truyens C, Merimi M, et al. P75 tumor necrosis factor-receptor shedding occurs as a protective host response during African trypanosomiasis. J Infect Dis 2004; 189: 527-539.
14. Millar AE, Sternberg J, McSharry C, Wei XQ, Liew FY & Turner CM. T-Cell responses during Trypanosoma brucei infections in mice deficient in inducible nitric oxide synthase. Infect Immun 1999; 67: 3334-3338.
15. Mabbott N & Sternberg J. Bone marrow nitric oxide production and development of anemia in Trypanosoma brucei-infected mice. Infect Immun 1995; 63: 1563-1566.
16. Amin DN, Rottenberg ME, Thomsen AR, et al. Expression and role of CXCL10 during the encephalitic stage of experimental and clinical African trypanosomiasis. J Infect Dis 2009; 200: 1556-1565.
17. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811.
18. Bosschaerts T, Guilliams M, Stijlemans B, et al. Tip-DC development during parasitic infection is regulated by IL-10 and requires CCL2/CCR2, IFN-γ and MyD88 signaling. PLoS Pathog 2010; 6: e1001045.
19. Fujita S, Seino K, Sato K, et al. Regulatory dendritic cells act as regulators of acute lethal systemic inflammatory response. Blood 2006; 107: 3656-3664.
20. Wakkach A, Fournier N, Brun V, Breittmayer J, Cottrez F & Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003; 18: 605-617.
21. Popov A & Schultze JL. IDO-expressing regulatory dendritic cells in cancer and chronic infection. J Mol Med 2008; 86: 145-160.
22. Cook CH, Bickerstaff AA, Wang JJ, et al. Spontaneous renal allograft acceptance associated with "regulatory" dendritic cells and IDO. J Immunol 2008; 180: 3103-3112.
23. Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2, 3-dioxygenase. Science 2002; 297: 1867-1870.
24. Svensson M, Maroof A, Ato M & Kaye PM. Stromal cells direct local differentiation of regulatory dendritic cells. Immunity 2004; 21: 805-816.
25. Delgado M, Gonzalez-Rey E & Ganea D. The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol 2005; 175: 7311-7324.
26. Stijlemans B, Baral TN, Guilliams M, et al. A glycosylphosphatidylinositol-based treatment alleviates trypanosomiasis-associated immunopathology. J Immunol 2007; 179: 4003-4014.
27. Carruthers VB & Cross GA. High-efficiency clonal growth of bloodstream- and insect-form Trypanosoma brucei on agarose plates. Proc Natl Acad Sci USA 1992; 89: 8818-8821.
28. Lanham SM & Godfrey DG. Isolation of salivarian trypanosomes from man and other mammals using DEAE-cellulose. Exp Parasitol 1970; 28: 521-534.
29. Konnai S, Mekata H, Mingala C, et al. Development and application of a quantitative real-time PCR for the diagnosis of Surra in water buffaloes. Infect Genet Evol 2009; 9: 449-452.
30. -ΔΔCT Method. Methods 2001; 25: 402-408.
31. Dunnett C. New tables for multiple comparisons with control. Biometrics 1964; 20: 482-491.
32. Kramer C. Extension of multiple range tests to group means with unequal numbers of replications. Biometrics 1956; 12: 307-310.
33. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
34. Peto R. Rank tests of maximal power against Lehmann-type alternatives. Biometrika 1972; 59: 472-475.
35. Hertz CJ & Mansfield JM. IFN-γ-dependent nitric oxide production is not linked to resistance in experimental African trypanosomiasis. Cell Immunol 1999; 192: 24-32.
36. Li SQ, Reid SA, Fung MC, Inoue N & Lun ZR. Analysis of gene expression profiles in the liver and spleen of mice infected with Trypanosoma evansi by using a cDNA microarray. Parasitol Res 2009; 104: 385-397.
37. Morrison LJ, McLellan S, Sweeney L, et al. Role for parasite genetic diversity in differential host responses to Trypanosoma brucei infection. Infect Immun 2010; 78: 1096-1108.
38. Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ & Coughlin SR. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc Natl Acad Sci USA 1994; 91: 2752-2756.
39. Gong X, Gong W, Kuhns DB, Ben-Baruch A, Howard OM & Wang JM. Monocyte chemotactic protein-2 (MCP-2) uses CCR1 and CCR2B as its functional receptors. J Biol Chem 1997; 272: 11682-11685.
40. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52: 145-176.
41. Ruffing N, Sullivan N, Sharmeen L, Sodroski J & Wu L. CCR5 has an expanded ligand-binding repertoire and is the primary receptor used by MCP-2 on activated T cells. Cell Immunol 1998; 189: 160-168.
42. Taub DD, Proost P, Murphy WJ, et al. Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest 1995; 95: 1370-1376.
43. Allavena P, Bianchi G, Zhou D, et al. Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol 1994; 24: 3233-3236.
44. Noso N, Proost P, Van Damme J & Schröder JM. Human monocyte chemotactic proteins-2 and 3 (MCP-2 and MCP-3) attract human eosinophils and desensitize the chemotactic responses towards RANTES. Biochem Biophys Res Commun 1994; 200: 1470-1476.
45. Alam R, Forsythe P, Stafford S, et al. Monocyte chemotactic protein-2, monocyte chemotactic protein-3, and fibroblast-induced cytokine. Three new chemokines induce chemotaxis and activation of basophils. J Immunol 1994; 153: 3155-3159.
46. Van Damme J, Proost P, Lenaerts JP & Opdenakker G. Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J Exp Med 1992; 176: 59-65.
47. Thiemermann C & Vane J. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur J Pharmacol 1990; 182: 591-595.
48. Kilbourn RG, Gross SS, Jubran A, et al. NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 1990; 87: 3629-3632.
49. Morris SM & Billiar TR. New insights into the regulation of inducible nitric oxide synthesis. Am J Physiol 1994; 266: 829-839.
50. Watanabe E, Hirasawa H, Oda S, Matsuda K, Hatano M & Tokuhisa T. Extremely high interleukin-6 blood levels and outcome in the critically ill are associated with tumor necrosis factor- and interleukin-1-related gene polymorphisms. Crit Care Med 2005; 33: 89-97.
51. Cauwels A. Nitric oxide in shock. Kidney Int 2007; 72: 557-565.
52. Feihl F, Waeber B & Liaudet L. Is nitric oxide overproduction the target of choice for the management of septic shock? Pharmacol Ther 2001; 91: 179-213.
53. Serbina NV & Pamer EG. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol 2006; 7: 311-317.
54. Tsou CL, Peters W, Si Y, et al. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest 2007; 117: 902-909.
55. Struyf S, Proost P, Vandercappellen J, et al. Synergistic up-regulation of MCP-2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effects. Eur J Immunol 2009; 39: 843-857.
56. Hoang A, Liu H, Juarez J, Aziz N, Kaye P & Svensson M. Stromal cell-derived CXCL12 and CCL8 cooperate to support increased development of regulatory dendritic cells following Leishmania infection. J Immunol 2010; 185: 2360-2371.
57. Grohmann U, Fallarino F, Bianchi R, et al. IL-6 inhibits the tolerogenic function of CD8 alpha (+) dendritic cells expressing indoleamine 2, 3-dioxygenase. J Immunol 2001; 167: 708-714.
58. Hwu P, Du MX, Lapointe R, Do M, Taylor MW & Young HA. Indoleamine 2, 3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000; 164: 3596-3599.
59. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A & Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189: 1363-1372.
60. Mellor AL, Keskin DB, Johnson T, Chandler P & Munn DH. Cells expressing indoleamine 2, 3-dioxygenase inhibit T cell responses. J Immunol 2002; 168: 3771-3776.
61. Guilliams M, Movahedi K, Bosschaerts T, et al. IL-10 dampens TNF/inducible nitric oxide synthase-producing dendritic cell-mediated pathogenicity during parasitic infection. J Immunol 2009; 182: 1107-1118.